The study, which is based on 2018 data, also found that U.S. drug spending increased by 76 percent between 2000 and 2017, with drug costs expected to jump even higher over the next decade.
It also found that U.S. prices for brand name drugs were an average of 3.44 times higher than other countries’ prices. However, U.S. prices for generic drugs were lower, averaging only 84 percent of other countries’ prices.
Total drug sales for all 33 countries examined in the study came to $795.2 billion. The U.S. accounted for 58 percent of these sales, even though drug sales from the country made up just 24 percent of the volume.
Prescription drug spending accounts for more than 10 percent of all U.S. healthcare spending, according to the study.
More articles on pharmacy:
Walgreens taps Starbucks exec as new CEO
Sanofi to manufacture 125M doses of Pfizer’s COVID-19 vaccine
Most pregnant women shouldn’t get COVID-19 vaccines, WHO says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
